35 results about "Myositis" patented technology

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

The invention discloses a drug for treating child acute benign myositis, aiming to solve the treatment problem of the child acute benign myositis. The drug is prepared from a plurality of Chinese medicinal herbs through processing; and the raw material formula and the weight proportions of the raw materials are as follows: 6-10 parts of aleuritopteris argentea fee, 8-15 parts of loofah sponge, 8-15 parts of six-eared blumea, 6-10 parts of angelica sinensis, 6-10 parts of the root of kudzu vine, 8-15 parts of papaya, 6-10 parts of radix ophiopogonis, 8-15 parts of adenophora tetraphylla and 3-6 parts of fissistigma bracteolatum. Clinical experiments prove that the drug disclosed by the invention is good in curative effect of treating the child acute benign myositis and high in safety, thereby being worth clinical application and popularization.

This invention relates to new uses of Bifidobacteria (particularly, although not exclusively, probiotic Bifidobacteria), and to food products, feed products, dietary supplements and pharmaceutical formulations containing them. The bacteria are suitable for the treatment of diabetes (particularly Type 2 diabetes), obesity and related conditions, metabolic syndrome, insulin resistance, and impaired glucose metabolism and consequences thereof, lowering tissue inflammation, treating hepatitis, myositis and cardiovascular conditions.

The present invention features palatable pharmaceutical compositions including sodium phenylbutyrate and methods for the treatment of inborn errors of metabolism (e.g., Maple Syrup Urine Disease or Urea Cycle Disorders), neurodegenerative disorders such as Parkinson's disease, spinal muscular atrophy, dystonia, or inclusion-body myositis with such compositions.

It is an object of the present invention to provide an excellent anti-inflammatory drug for external use that is used for treating inflammation observed in animals (myositis, arthritis, neuritis, tendinitis, tenosynovitis, desmitis, bruise, sprain, etc.), and in particular, for the treatment of bowed tendon observed in horses. The solution of the present invention is an external pharmaceutical composition for preventing or treating inflammation observed in animals, which comprises loxoprofen or a salt thereof as an active ingredient.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hapatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Disclosed are 1,3-Dioxoindene derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The 1,3-Dioxoindene derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, flu, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Disclosed are indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, Polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can be useful as an active ingredient of a pharmaceutical composition for the prevention or treatment of viral diseases including poliomyelitis, paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myositis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinusitis or otitis media.

Compositions and methods for assessing inflammation in a subject. The present disclosure provides compositions for labeling leukocytes with a 19F-containing perfluoropolyether molecule ex vivo. In some examples, the leukocytes are obtained from the patient, enriched in a whole blood fraction, and then labeled. The labeled cells may be re-introduced into the patient. The leukocytes may accumulate at a site of inflammation, thus permitting non-invasive evaluation of inflammation in patients. The present methods provide a tool for assessing inflammation in a wide variety of autoimmune diseases and may have particular utility in intestinal diseases such as Crohn's disease, ulcerative colitis, inflammatory bowel disease, and cardio myositis.

Disclosed are novel benzodiazepine derivatives and uses thereof. The present disclosure provides compounds and compositions capable of extending lifespan, and methods of use thereof. The compounds, conjugates, and pharmaceutical compositions provided by the present invention can be used to inhibit abnormal cell growth or treat proliferative disorders in mammals, and can also be used to treat mammalian conditions such as cancer, rheumatoid arthritis, multiple sclerosis, graft-versus-host disease (GVHD), transplant rejection, lupus, myositis, infection, immunodeficiency such as AIDS and inflammatory diseases, thereby extending lifespan.

The invention discloses a kit and a method for detecting autoantibodies of myositis and myasthenia gravis in human body fluid. The detection kit includes a test strip, a working solution and a closed protein solution; the detection method includes mixing the working solution and the closed protein solution to form sample dilution solution, add the sample to be tested in the sample diluent; add the sample to be tested dropwise on the sample pad of the test strip; remove the absorbent pad and sample pad on the test strip, wash the carrier film, and then wash the carrier film The absorbent pad and the gold standard pad are fixed on both ends of the carrier film; the end of the gold standard pad of the test strip is immersed in the working solution, and the color development is observed. In the detection process of the present invention, the sample chromatographic method is inverted chromatography, and the carrier membrane washing method is ultrasonic washing, which effectively increases the detection sensitivity and specificity, and the strong positive serum can still detect antibodies after being diluted more than 10,000 times.